Willekens, Christophe https://orcid.org/0000-0001-9814-8537
Bazinet, Alexandre
Chraibi, Samy
Bataller, Alex https://orcid.org/0000-0002-6085-2745
Decroocq, Justine
Arani, Naszrin
Carpentier, Benjamin
Rausch, Caitlin https://orcid.org/0000-0002-4166-5717
Lebon, Delphine
Maiti, Abhishek
Gauthier, Nicolas
Short, Nicholas https://orcid.org/0000-0002-2983-2738
Bonnet, Sarah
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Khalife-Hachem, Sabine
Swaminathan, Mahesh https://orcid.org/0000-0001-5959-397X
Micol, Jean-Baptiste https://orcid.org/0000-0003-0934-294X
Pasquier, Florence
Marzac, Christophe
Roos-Weil, Damien
Pascal, Laurent
Daver, Naval https://orcid.org/0000-0001-7103-373X
Kadia, Tapan https://orcid.org/0000-0002-9892-9832
Bouscary, Didier
Ravandi, Farhad https://orcid.org/0000-0002-7621-377X
Pages, Arnaud https://orcid.org/0000-0002-2337-8693
Kantarjian, Hagop https://orcid.org/0000-0002-1908-3307
De Botton, Stéphane
DiNardo, Courtney https://orcid.org/0000-0001-9003-0390
Article History
Received: 21 January 2025
Revised: 2 March 2025
Accepted: 26 March 2025
First Online: 17 April 2025
Competing interests
: CW: Consultant/Advisory Boards: BMS, Abbvie. NG: Consultant/Advisory Boards: BMS. JBM: Honoraria: Jazz Pharmaceuticals, Astellas Pharma, SERVIER. Consultant/Advisory Boards: AbbVie, Gilead Sciences. Travel, Accommodations, Expenses: AbbVie. CM: Research funding: Incyte. LP: Consultant/Advisory Boards: Janssen, Takeda, Abbvie, Gilead, Kephren and Résilience. SDB: Consultant/Advisory Boards: Servier, BMS, GSK, Syndax Pharmaceuticals, and Remix Therapeutics. Honoraria from BMS, AbbVie, Servier, Jazz Pharmaceuticals, Astellas, and Loxo Oncology. Speakers’ bureau: Servier, BMS, Jazz Pharmaceuticals, Astellas, and AbbVie. Research funding: Forma Therapeutics and Auron Therapeutics. CD: Consultant/Advisory Boards: Abbvie, AstraZeneca, Astellas, BMS, Genentech, GenMab, GSK, ImmuneOnc, Notable Labs, Rigel, Schrodinger, Servier. CDD is supported by the LLS Scholar in Clinical Research Award. ABazinet, SC, ABataller, JD, NA, BC, CR, DL, AM, NS, SB, KS, SKH, MS, FP, DRW, ND, TK, DB, FR, AP and HK had no conflict of interest.